Granules India Arm Gets US FDA Nod for Product from Hyderabad, India Unit

MT Newswires Live

Nov 11, 2025

Granules Life Sciences, a wholly-owned subsidiary Granules India (NSE:GRANULES, BOM:532482) has received US Food and Drug Administration (US FDA) approval for a product that was the subject of a pre-approval inspection (PAI) at its unit in Hyderabad, India, according to a Tuesday filing to the Indian stock exchanges.

The inspection was conducted between July 28 and Aug. 1, which conculded with was one observation during that inspection.

With this approval, the Granules Life facility is now deemed approved by the US FDA. It is the first approval from the American regulator for the Granules Life site.

The same product is already approved and manufactured at Granules' Gagillapur facility and the company plans to launch the approved product in the US market soon.

The comapny's shares were down over 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582306403"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582306403\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582306403?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 14:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582306403","market":"us","top_or_hot":-1,"title":"Granules India Arm Gets US FDA Nod for Product from Hyderabad, India Unit","media":"MT Newswires Live","content":"<html><body><p> Granules Life Sciences, a wholly-owned subsidiary Granules India (NSE:GRANULES, BOM:532482) has received US Food and Drug Administration (US FDA) approval for a product that was the subject of a pre-approval inspection (PAI) at its unit in Hyderabad, India, according to a Tuesday filing to the Indian stock exchanges.</p><p>The inspection was conducted between July 28 and Aug. 1, which conculded with was one observation during that inspection.</p><p>With this approval, the Granules Life facility is now deemed approved by the US FDA. It is the first approval from the American regulator for the Granules Life site.</p><p>The same product is already approved and manufactured at Granules' Gagillapur facility and the company plans to launch the approved product in the US market soon.</p><p>The comapny's shares were down over 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Granules India Arm Gets US FDA Nod for Product from Hyderabad, India Unit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGranules India Arm Gets US FDA Nod for Product from Hyderabad, India Unit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-11 14:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Granules Life Sciences, a wholly-owned subsidiary Granules India (NSE:GRANULES, BOM:532482) has received US Food and Drug Administration (US FDA) approval for a product that was the subject of a pre-approval inspection (PAI) at its unit in Hyderabad, India, according to a Tuesday filing to the Indian stock exchanges.</p><p>The inspection was conducted between July 28 and Aug. 1, which conculded with was one observation during that inspection.</p><p>With this approval, the Granules Life facility is now deemed approved by the US FDA. It is the first approval from the American regulator for the Granules Life site.</p><p>The same product is already approved and manufactured at Granules' Gagillapur facility and the company plans to launch the approved product in the US market soon.</p><p>The comapny's shares were down over 1% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4543","symbol_name":"AI","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2582306403","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582306403","pubTimestamp":1762843415,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Granules Life Sciences, a wholly-owned subsidiary Granules India  has received US Food and Drug Administration  approval for a product that was the subject of a pre-approval inspection  at its unit in Hyderabad, India, according to a Tuesday filing to the Indian stock exchanges.The inspection was conducted between July 28 and Aug. 1, which conculded with was one observation during that inspection.With this approval, the Granules Life facility is now deemed approved by the US FDA. It is the first approval from the American regulator for the Granules Life site.The same product is already approved and manufactured at Granules' Gagillapur facility and the company plans to launch the approved product in the US market soon.The comapny's shares were down over 1% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4543":"AI","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","PAI.AU":"Platinum Asia Investments Ltd","PAI":"Western Asset Income Fund","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","BK4609":"英伟达持仓股","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","BK4588":"碎股","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","BK4141":"半导体产品","BK4585":"ETF&股票定投概念","IE00BMPRXQ63.HKD":"NEUBERGER BERMAN NEXT GENERATION CONNECTIVITY FUND \"A\" (HKDHDG) ACC"},"translate_title":"印度颗粒分公司的产品获得美国FDA批准来自印度海得拉巴子公司的产品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAI.AU":1,"MNDmain":1.5,"PAI":1},"content_text":"Granules Life Sciences, a wholly-owned subsidiary Granules India (NSE:GRANULES, BOM:532482) has received US Food and Drug Administration (US FDA) approval for a product that was the subject of a pre-approval inspection (PAI) at its unit in Hyderabad, India, according to a Tuesday filing to the Indian stock exchanges.The inspection was conducted between July 28 and Aug. 1, which conculded with was one observation during that inspection.With this approval, the Granules Life facility is now deemed approved by the US FDA. It is the first approval from the American regulator for the Granules Life site.The same product is already approved and manufactured at Granules' Gagillapur facility and the company plans to launch the approved product in the US market soon.The comapny's shares were down over 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}